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Abstract
Background: Atrial endocrine function was established in the second half of the 20th century,
confirming the role of artial natriuretic peptide (ANP) and brain natriuretic peptide (BNP)
in the physiology of the cardiovascular system. The present study was undertaken to evaluate
changes in ANP and echocardiographic parameters within the first month after VVI and DDD
pacemaker implantation and to evaluate correlations between the parameters.
Methods: The study population consisted of group I — 20 VVI patients aged 71–90 years
(mean age 77.5 ± 5.9) and group II — 20 DDD/VDD patients aged 49–81 years (mean age
68.9 ± 11). Fifteen healthy volunteers aged 58–80 years (mean age 72.7 ± 2.8) served as
controls. Correlations between ANP levels and cardiac cavity dimensions and between ANP
and parameters of renal function were studied.
Results: Blood levels of ANP decreased after pacemaker implantation: in the VVI group from
168.61 ± 81.95 pg/1000 µL to 118.04 ± 61.06 pg/1000 µL at 7 days and to 121.4 ± 71.90 pg/
/1000 µL at 30 days; and in the DDD/VDD group from 134.89 ± 83.11 pg/1000 µL to 104.96 ±
± 57.09 pg/1000 µL at 7 days and to 110.82 ± 53.32 pg/1000 µL at 30 days. There was
a significant correlation between ANP levels and left atrial size in the DDD/VDD group —
0.598 (p = 0.005) and 0.593 (p = 0.005) and left ventricular dimensions — 0.499 (p = 0.024)
and 0.485 (p = 0.030).
Conclusions: ANP decreases significantly after pacing implementation in patients selected
for implantation of VVI and DDD/VDD pacemakers. ANP correlates significantly with echo-
cardiographic measurements in patients selected for DDD/VDD pacemakers, but no significant
correlation is observed in VVI patients qualifying for permanent pacemaker due to atrio-
ventricular block. (Cardiol J 2009; 16, 2: 157–163)
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Introduction
Assessment of natriuretic peptides in blood
provides important clinical information, especially
in cases of heart failure, arterial hypertension, co-
ronary artery disease, and cardiac arrhythmias.
The endocrine function of the heart was first
established in 1956 when Kisch described osmophi-
lic granules in the atrial muscle of a guinea pig [1].
In 1981 de Bold et al. [2] reported that rat atrial
extracts given intravenously had a stimulatory ef-
fect on urinary water and sodium excretion.
The most important natriuretic peptides are:
atrial natriuretic peptide (ANP), consisting of 28 ami-
no acids; brain natriuretic peptide (BNP), consisting
of 32 amino acids; and C-type natriuretic peptide
(CNP), consisting of 22 amino acids [3, 4]. The prin-
cipal stimulus for ANP secretion, and therefore in-
crease in serum ANP concentration, is mechanical
distension of atrial myocytes. Increased atrial wall
tension causes ANP secretion. Increased atrial me-
chanical load raises the ANP concentration in blo-
od serum [5, 6].
Mechanical atrial wall stretch is linked to in-
creased ANP secretion [7]. It is the first response
to unfavourable hemodynamic changes. A further
compensatory mechanism involves vasodilator ef-
fects. Urinary sodium excretion and diuresis are
increased whereas secretion of vasopressin, aldo-
sterone, and renin is reduced [8]. In response, ANP
concentration and BNP secretion are increased.
Assessment of ANP and BNP concentrations
is a useful tool for monitoring patients with heart
failure. Clinical evidence shows that BNP is a pre-
dictor of morbidity and mortality in heart failure
patients [9, 10]. It is especially important in the
asymptomatic phase of the disease when BNP levels
may predict the development of symptoms [11, 12].
In 1958 Sening in Stockholm was the first per-
son to implant a cardiac pacemaker in a patient with
a third-degree atrioventricular block [13, 14]. The
first pacemaker implantation in Poland was perfor-
med by Kieturakis in Gdansk in 1963 [14]. Since
that time, the situation has changed and we have
witnessed tremendous progress in cardiac pacema-
kers and pacing leads. The indications for cardiac
pacing have extended beyond the management of
atrioventricular blocks and conduction disorders [14]
and include cardiac resynchronization therapy, pa-
cing to prevent atrial fibrillation, and permanent
pacing in long QT syndrome [15].
Patients with severe atrioventricular conduction
defects receive VVI, DDD, and VDD pacemakers.
The present study was undertaken to evaluate
changes in ANP and echocardiographic parameters
during the first month after VVI and DDD pacema-
ker implantation and to evaluate correlations among
studied parameters.
Methods
The study included a total of 55 patients of
whom 40 had second- and third-degree atrioventri-
cular blocks. Group I consisted of 20 patients with
an implanted VVI pacemakers, aged 71–90 years
(mean age 77.5 ± 5.9 years), and group II, 20 pa-
tients with DDD/VDD pacemakers, aged 49–81 ye-
ars (mean age 68.9 ± 11 years). The control group
(group III) consisted of 15 healthy volunteers ran-
ging in age from 58 to 80 years (mean age 72.7 ±
± 2.8 years). Those with cardiac defects, acute my-
ocardial infarction, unstable angina pectoris, decom-
pensated heart failure, acute and chronic respira-
tory diseases, anemia, thyroid diseases, or neopla-
stic processes were excluded from the study.
Patients were entered for the study if their ECG
strips or Holter recording showed second- or third-
-degree atrioventricular conduction defects and
they qualified for permanent pacing. Table 1 sum-
marizes the clinical data.
VVI pacemakers were implanted in patients
with paroxysmal block and atrioventricular conduc-
tion defects without retrograde ventriculoatrial con-
duction and in patients with motoric dysfunction.
DDD/VDD pacemakers were implanted in physical-
ly active patients (irrespective of age), patients with
Table 1. Clinical data.
Clinical data Group I (n = 20) Group II (n = 20) P
Previous myocardial infarction 5 (25%) 10 (50%) > 0.05
Stable coronary disease 14 (70%) 14 (70%) > 0.05
Compensated heart failure 17 (85%) 13 (65%) > 0.05
Type 2 diabetes 6 (30%) 2 (10%) > 0.05
Hypercholesterolemia 8 (40%) 15 (75%) < 0 05
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retrograde ventriculoatrial conduction, and in pa-
tients with clinical manifestations of heart failure.
Plasma aANP was measured in all the three
groups. Blood samples for the determination of pla-
sma aANP were drawn before, and 7 days and
30 days after, pacemaker implantation. In the con-
trol group, aANP concentration was measured only
once. Blood was sampled at rest (supine position)
from patients arriving in the morning until noon. Six
millilitres of full blood was sampled in tubes conta-
ining 1 mg/mL EDTA and 500–1000 KIU/mL Tra-
sylol and centrifuged at 4°C for 30 min at 2000 g.
Isolated serum was frozen at –15 to –30°C. ANP
concentration was measured using double-antibo-
dy radioimmunoassay kit (Human aANP-RIA sys-
tem RPA 512, Amersham) [16].
Transthoracic echocardiography was perfor-
med in all the patients and the controls. Echocar-
diograms were obtained from pacemaker patients
on three occasions: before, 7 days, and 30 days after
the system placement. The controls underwent
echocardiographic examination only once. The stu-
dy was performed in the morning between 9.00 and
12.00 with an Acuson Sequoya device and 3.5 MHz
probe.
Those with poor-quality echocardiographic
images were excluded from further analysis. The
value of each parameter was averaged from three
measurements. The study was performed on the
patients in the left decubitus position. M-mode ima-
ges were obtained in the parasternal long and short
axis and in apical two- and four-chamber views.
Doppler technique was used to measure the flow
of blood. The following echocardiographic parame-
ters were selected for analysis:
Left atrial parameters
LA max [cm] — maximum left atrial dimen-
sion in the M-mode parasternal long axis view
— measured from the left atrial posterior wall to
the inner aortic surface.
LA min [cm] — minimum left atrial dimen-
sion in the M-mode parasternal long axis view
— measured from the left atrial posterior wall to
the inner aortic surface.
LATEF — left atrial total emptying fraction
= LA max – LA min/LA min [17–19].
Parameters of left ventricular
systolic function
LVEDD [cm] — left ventricular end-diastolic
dimension in the M-mode parasternal long axis
view, immediately below the mitral valve — me-
asured between the posterior wall inner surface and
the left ventricular inner surface of the ventricular
septum.
LVESD [cm] — left ventricular end-systolic
dimension in the M-mode parasternal long axis
view, immediately below the mitral valve — me-
asured between the posterior wall inner surface and
the left ventricular inner surface of the ventricular
septum.
EF — left ventricular ejection fraction calcu-
lated according to the Teicholtz formula.
Creatinine clearance was measured using
a colorimetric kinetic Jaffe assay. In an alkaline envi-
ronment, creatinine forms coloured complexes with
picric acid. Absorption enhancement measured for
500 nm wavelength is proportional to creatinine
concentration. Creatinine is measured in serum and
daily urine. Total creatinine urinary excretion is
1.0–2.5 g/day. Creatinine clearance reference values
are 75–110 mL/min. Measurements are made using
an automated analyzer Ra 1000 Technicon [20].
Quantitative variables were presented as the
arithmetic mean, median (if not normally distribu-
ted), and standard deviation [21].
Statistical analysis was performed using para-
metric Student’s t-test and non-parametric U Mann-
-Whitney test. ANOVA was used for the normally
distributed data. The RIR Turkey test was used for
comparisons [21].
The study was approved by the local bioethi-
cal committee and all patients gave their informed
consent.
Results
Assessment of the changes in blood ANP con-
centrations during the study revealed significant
differences in group I (VVI pacing) and in group II
(DDD pacing) between baseline and 7 days, and
between baseline and 30 days after implantation.
Left atrial systolic dimension at baseline diffe-
red significantly from that at 30 days in group I
(VVI pacing). Left atrial diastolic dimension at base-
line differed significantly from that at 7 days and at
30 days in group I (VVI pacing). There was a signi-
ficant difference in left atrial total emptying fraction
between baseline and day 30, and between day 7 and
day 30, in group II (DDD pacing).
Left ventricular systolic dimension at baseline
differed significantly from that at 7 days in group II
(DDD pacing). Left ventricular ejection fraction dif-
fered significantly between baseline and day 7 and
between baseline and day 30 in group I (VVI pacing).
There was a significant difference in blood urea
levels between baseline and day 7, and between
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baseline and day 30, as well as between day 7 and
day 30, in group I (VVI pacing). Creatinine clearan-
ce differed significantly between baseline and day
30 and between day 7 and day 30 in both groups
(VVI and DDD pacing).
After pacemaker implantation, ANP concentra-
tion decreased in the VVI and DDD/VDD groups.
We observed significant differences. We did not
observe significant differences between  left atrial
and left ventricular dimensions in either group. Left
atrial total emptying fraction in the group DDD/
/VDD and left ventricular ejection fraction in the
group VVI improved after pacemaker implantation.
Renal parameters improved in both groups. Table 2
summarizes changes in ANP and echocardiographic
parameters over time in patients with VVI and DDD
pacing.
At baseline in patients with second- and third-
degree atrioventricular conduction defects there
was a significant correlation between serum ANP
concentration and maximum and minimum left atrial
dimension (p < 0.05) in group II. The correlation
coefficients were 0.598 and 0.593, respectively.
There was also a significant correlation between
ANP levels and left ventricular diastolic and systolic
dimensions in group II (p < 0.05). The correlation
coefficients were 0.499 and 0.485, respectively.
In the control group (group III), we found no
significant correlation between ANP levels and left
atrium, or left ventricular dimension and renal func-
tion. Table 3 summarizes the assessment of the
correlations. Figures 1–3 show significant correla-
tion coefficients between blood ANP concentrations
and left atrial and left ventricular function parame-
ters.
Discussion
At baseline, prior to permanent pacemaker im-
plantation, there was a positive correlation between
serum ANP concentration and left atrial minimum and
maximum dimensions in patients with DDD/VDD
pacing systems. In these patients there was also
a positive correlation between ANP concentration and
left ventricular systolic and diastolic dimension. In all
patients with VVI and DDD/VDD pacing systems
Table 2. Changes in atrial natriuretic peptide and echocardiographic parameters over time in patients
with VVI and DDD pacing.
Parameters Before 7 days after 30 days after P
7 days 30 days 30 days
 vs. baseline  vs. baseline  vs. 7 days
VVI
ANP [pg/1000 mL] 168.61±81.95 118.04±61.06 121.40±71.90 < 0.01 < 0.05 NS
LASD [mm] 32.40±5.63 31.35±4.36 29.40±5.53 NS < 0.05 NS
LADD [mm] 42.95±4.75 40.75±3.97 39.60±4.13 < 0.05 < 0.01 NS
LATEF (%) 24.50±6.59 22.80±7.17 25.95±8.74 NS NS NS
LVSD [mm] 37.05±7.36 36.80±7.91 36.55±7.21 NS NS NS
LVDD [mm] 54.80±9.79 54.00±9.15 53.60±6.57 NS NS NS
LVEF (%) 53.05±6.07 54.85±5.22 55.15±5.99 < 0.01 < 0.05 NS
Urea [mg/dL] 56.45±21.59 52.10±19.90 42.45±7.95 < 0.05 < 0.01 < 0.05
CC [ml/min] 72.07±19.31 76.12±17.80 84.98±17.91 NS < 0.01 < 0.01
DDD/VDD
ANP [pg/1000 mL] 134.89±83.11 104.96±57.09 110.82±53.32 < 0.01 < 0.05 NS
LASD [mm] 29.05±6.29 27.70±5.33 27.00±5.95 NS NS NS
LADD [mm] 37.55±7.07 37.25±6.17 37.70±6.35 NS NS NS
LATEF (%) 22.95±7.47 25.05±8.23 28.05±9.06 NS < 0.01 < 0.05
LVSD [mm] 39.35±10.47 37.90±10.32 37.65±9.47 < 0.05 NS NS
LVDD [mm] 55.90±9.49 55.70±9.55 54.75±8.21 NS NS NS
LVEF (%) 53.75±10.00 55.05±10.15 54.40±10.70 NS NS NS
Urea [mg/dL] 47.30±14.91 46.40±13.06 44.80±11.40 NS NS NS
CC [ml/min] 82.32±15.85 84.63±13.21 96.86±18.22 NS < 0.01 < 0.01
CC — creatinine clearance; LVEF — left ventricular ejection fraction; LVDD — left ventricular diastolic dimension; LVSD — left ventricular systolic
dimension; LATEF — left atrial total emptying fraction; LADD — left atrial diastolic dimension; LASD — left atrial systolic dimension
implantation implantation   implantation
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there was a positive correlation between ANP con-
centration and left atrial maximum dimension.
At 7 days after permanent pacemaker implan-
tation there was a significant correlation between
serum ANP concentration and creatinine clearan-
ce in patients with DDD/VDD pacing systems. The-
re was also a significant correlation between ANP
values and left atrial maximum dimension in all pa-
tients with VVI and DDD/VDD pacing systems.
At 30 days after permanent pacemaker implan-
tation there was a significant correlation between
serum ANP concentration and left ventricular sy-
stolic and diastolic dimension in patients with VVI
pacing systems. There was also a significant corre-
lation between ANP concentration, left ventricular
Table 3. Correlation between blood atrial natriuretic peptide concentrations and selected parameters of
left atrial and left ventricular function, and renal function, in groups I, II, and III.
Group r/p Left atrial function Left ventricular function Renal function
LA max LA min LATEF LVEDD LVESD EF Urea Creatinine CC
I r 0.038 –0.057 0.221 –0.128 –0.044 –0.349 –0.336 –0.320 0.057
p 0.871 –0.244 0.347 –0.548 –0.188 0.131 0.146 0.168 0.810
II r 0.598 0.593 –0.124 0.499 0.485 –0.120 0.259 -0.001 0.257
p 0.005 0.005 0.601 0.024 0.030 0.612 0.269 0.994 0.272
III r –0.001 –0.254 0.159 0.285 0.189 0.007 –0.175 –0.028 –0.267
p 0.994 0.360 0.571 0.302 0.498 0.979 0.531 0.919 0.334
EF — ejection fraction; LVEDD — left ventricular end-diastolic dimension; LVESD — left ventricular end-systolic dimension; CC — creatinine clearance;
LA — left atrial; LATEF — left atrial total emptying fraction
Figure 1. Correlation between blood atrial natriuretic
peptide (ANP) concentrations and left atrial diastolic
dimension (LADD) prior to pacemaker implantation in
group II (DDD); r = 0.598, p = 0.005.
Figure 2. Correlation between blood atrial natriuretic
peptide (ANP) concentrations and left ventricular systo-
lic dimension (LVSD) prior to pacemaker implantation
in group II (DDD); r = 0.485, p = 0.030.
systolic and diastolic dimension, and left ventricu-
lar ejection fraction in all patients with VVI and
DDD/VDD pacing systems.
There was a positive correlation between chan-
ges in ANP concentration and changes in left atrial
total emptying fraction in patients with VVI pacing
systems.
In patients with DDD/VDD pacing systems
there was a positive correlation between changes
in ANP concentration and changes in left ventricu-
lar systolic dimension.
In all patients with VVI and DDD/VDD pacing
systems there was a significant correlation betwe-
en changes in ANP concentration and left ventri-
cular systolic dimension.
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At 30 days after permanent pacemaker implan-
tation there was a significant correlation between
changes in serum ANP concentration and changes
in left ventricular minimum dimension in patients
with DDD/VDD pacing systems. There was also
a significant correlation between changes in ANP
concentration and changes in left atrial minimum
dimension in all patients with VVI and DDD/VDD
pacing systems.
Comparing serum ANP concentrations in pa-
tients with VVI and DDD/VDD pacing systems, we
found that serum ANP decreased in patients with
both types of pacing devices. Further analysis of
absolute ANP values revealed that patients with
DDD/VDD pacing devices are characterized by in-
creased dynamics of reduction in ANP concentra-
tion after permanent pacemaker implantation.
VVI pacemakers were implanted in patients
with paroxysmal block and atrioventricular conduc-
tion defects without retrograde ventriculoatrial con-
duction, and in patients with motoric dysfunction.
DDD/VDD pacemakers were implanted in physical-
ly active patients (irrespective of age), patients with
retrograde ventriculoatrial conduction, and patients
with clinical manifestations of heart failure. Measu-
rement of blood ANP concentrations prior to pace-
maker implantation had no impact on the choice of
pacing mode. If the information on ANP levels had
been available earlier, it would have been possible
to alter patient selection criteria for pacing mode.
Changes in blood ANP concentrations might have
also been a result of the natural course of the dise-
ase. It is of vital importance to analyze carefully the
patient’s clinical data, taking into account the ma-
nifestations of heart failure (Table 1).
The correlation between ANP levels and other
parameters is of major interest. Analysis revealed
that ANP values are linked to parameters of left
atrial function. The relationship is especially strong
in patients with DDD/VDD pacing devices. In such
patients the reduction in ANP secreted from car-
diac atria is associated with improved left atrial
hemodynamics and renal function.
The presence of positive correlations betwe-
en ANP concentrations and left atrial and left ven-
tricular dimensions, as well as renal function para-
meters, may provide a clue to the choice of pacing
mode in a given group of patients. Routine asses-
sment of ANP levels prior to pacemaker implanta-
tion would provide useful prognostic information
from a clinical viewpoint.
Analysis of ANP levels prior to pacemaker
implantation and at consecutive time intervals de-
monstrates higher ANP concentrations and larger
changes in its levels in patients with VVI pacing.
There is a clear correlation between ANP changes
and left atrial function parameters. As left ventri-
cular function was comparable in both groups, it may
be concluded that, based on ANP assay, the patients
had been inappropriately selected for pacemaker
implantation. VVI pacemakers had been implanted
in patients with higher ANP levels, that is, in those
with more advanced heart failure. According to gu-
idelines, such patients should receive a DDD pace-
maker. The information on ANP levels was not ava-
ilable prior to patient selection for pacemaker im-
plantation in this study. It appears that ANP assay
is an important prognostic tool supporting the dia-
gnostic process in patients qualifying for pacema-
ker therapy.
Left ventricular and left atrial function in
patients with left ventricular impairment was exa-
mined in the large multicentre clinical study,
CONSENSUS II. Erriksson et al. performed a sub-
group analysis in 53 patients with post-myocardial
infarction left ventricular impairment [22]. They as-
sessed the correlation between left atrial dimen-
sion, left ventricular dimension and serum ANP
concentration, measured by radioimmunology. The-
re was a negative correlation between ANP and left
atrial dimension (r = –41), and a positive correla-
tion between left ventricular systolic parameters
and ANP secretion measured by radioimmunology
(r = 40).
In a similar study, Irzmański et al. [17] asses-
sed ANP and BNP levels in patients with idiopathic
arterial hypertension and left ventricular hypertrophy.
Figure 3. Correlation between blood atrial natriuretic
peptide (ANP) concentrations and left ventricular systo-
lic dimension (LVSD) at 30 days after pacemaker im-
plantation in group II (DDD); r = 0.495, p = 0.040.
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They found a positive correlation between ANP and
BNP levels and left ventricular posterior wall thick-
ness, ventricular septal thickness, and left ventricu-
lar mass index. Increased ANP and BNP levels were
predictors of hypertension complications.
In another study, Irzmański et al. [18] asses-
sed ANP and BNP levels in relation to endothelin-1
in patients with arterial hypertension. There was
a strong correlation between ANP, BNP, and en-
dothelin-1 levels and left ventricular posterior wall
thickness, and between ventricular septal thickness
and left ventricular mass index on echocardiogra-
phy in hypertensives.
Hayashi et al. [19] demonstrated a similar cor-
relation between ANP levels and left atrial dimen-
sion in patients with mitral stenosis.
Summing up, the correlation between ANP le-
vels and echocardiographic parameters of the left
atrium and left ventricle varies and may provide
useful clinical information.
Conclusions
1. ANP decreases significantly after implementa-
tion of pacing in patients qualified for implan-
tation of VVI and DDD/VDD pacemakers.
2. ANP correlates significantly with echocardio-
graphic measurements in patients qualified for
DDD/VDD pacemakers, but no significant cor-
relation is observed in VVI patients qualified
for pacemaker due to atrioventricular blocks.
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